2nd Biosimilar Market Access and Commercialization Strategies Summit

Conference themes
The FDA's approval of the first wave of biosimilars in 2015 cleared the way for manufacturers to make lower-cost versions of expensive biologic drugs, saving patients money and improving access to vital medications. There is a significant market opportunity ahead for biosimilar developers if they can figure out a strategic plan to enhance the commercialization of the biosimilar.

Professional congress organizer (PCO)
ExL Events

Notes
Speakers: Jay Brown, Sr. Director Outpatient Pharmacy Services, NOVANT HEALTH, INC, Niraj Chhaya, Risk Management, Biosimilars, BOEHRINGER INGELHEIM LIMITED, Mona Chitre, Vice President of Pharmacy, EXCELLUS BLUECROSS BLUESHIELD & more.

https://go.evvnt.com/228702-1?pid=4832

Ms. Taryn O'Donnell